Journey Medical targets expanded Emrosi coverage and EBITDA growth through 2026 amid robust prescription demand (NASDAQ:DERM)March 26, 2026
Share Facebook Twitter LinkedIn Pinterest Email Woodside assumes control of Beaumont plant, delays lower-carbon ammonia production
Journey Medical targets expanded Emrosi coverage and EBITDA growth through 2026 amid robust prescription demand (NASDAQ:DERM)March 26, 2026
Modiv Industrial outlines accelerated asset recycling, targets 100% manufacturing portfolio within 24 months (NYSE:MDV)March 26, 2026
Celcuity outlines potential $2.5B annual peak revenue for gedatolisib amid pivotal clinical milestones and commercial launch preparations (NASDAQ:CELC)March 26, 2026
By Press Room
By Press Room
By Press Room
